jab-3312
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Sep 30, 2019 (NCT04045496)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Pancreatic Ductal · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 1
- Neoplasms · Phase 1/Phase 2
- Proto-Oncogene Proteins p21(ras) · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 3
- Squamous Cell Carcinoma of Head and Neck · Phase 1
Mechanism of action
- Protein-tyrosine phosphatase 2CALLOSTERIC ANTAGONIST
PTPN11 allosteric antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06416410 | Phase 3 | Aug 7, 2024 | Jacobio Pharmaceuticals Co., Ltd. |
| NCT05288205 | Phase 1/Phase 2 (Phase 2) | Apr 14, 2022 | Jacobio Pharmaceuticals Co., Ltd. |
| NCT04720976 | Phase 1/Phase 2 (Phase 2) | Mar 23, 2021 | AbbVie, Jacobio Pharmaceuticals Co., Ltd. |
| NCT04121286 | Phase 1 | Nov 30, 2019 | Chinese Academy of Medical Sciences, Jacobio Pharmaceuticals Co., Ltd. |
| NCT04045496 | Phase 1 | Sep 30, 2019 | Jacobio Pharmaceuticals Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jacobio Pharmaceuticals Co., Ltd. | For profit | 5 | 5 | 3 | 2019 |
| AbbVie | For profit | 1 | 0 | 1 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1